MCL Literature Feed

This CLL study reveals venetoclax rapidly activates a BAFF-driven survival axis in residual tumor cells, a key resistance mechanism potentially targetable in MCL to deepen BCL2i responses.

Epigenetic profiling reveals a unique DNA methylation signature for B-cell prolymphocytic leukemia, providing a novel biomarker to differentiate it from its mimics, including mantle cell lymphoma.

The novel, chemotherapy-free triplet of alisertib, ibrutinib, and rituximab demonstrates clinical activity in MCL, providing a new therapeutic strategy for likely relapsed/refractory patients.

This large retrospective study of 476 MCL patients aged ≥80 provides crucial real-world outcome data, informing treatment selection and expectations in the very elderly population.

This case report illustrates the diagnostic challenge of distinguishing mantle cell lymphoma from chronic lymphocytic leukemia, emphasizing the critical role of specific pathological and cytogenetic markers for accurate diagnosis.

This preclinical study explains bortezomib-induced pulmonary toxicity, showing it increases endothelial RhoA/RhoC proteins, which synergize with inflammation to cause vascular hyperpermeability and capillary leak syndrome.

In newly diagnosed MCL, PET/CT-based bone marrow assessment has greater prognostic value than biopsy and is incorporated into a new MCL-PET-I index for improved risk stratification.

This case report describes a rare MCL CNS relapse presenting as Horner syndrome and oculomotor nerve palsy, highlighting the need for CSF analysis in patients with atypical neurological symptoms, even with normal imaging.

This systematic review of brexu-cel for relapsed/refractory MCL reveals conflicting cost-effectiveness conclusions across different countries, highlighting major uncertainties for health systems considering its adoption and reimbursement.

This general review contextualizes CAR T-cell therapy, including its approved use in mantle cell lymphoma, within the broader landscape of cellular therapies, summarizing its efficacy and common toxicities.

This review highlights that TP53-mutated MCL represents a distinct high-risk entity with poor outcomes to chemoimmunotherapy, underscoring the urgent need for novel, non-chemotherapy frontline approaches in these patients.

Reviewing the TRIANGLE trial, this paper argues that adding ibrutinib to frontline induction makes omitting autologous stem cell transplant consolidation a non-inferior, less toxic option for young patients.

This review outlines the clinical landscape and practical application of CAR-T and bispecific antibodies for relapsed/refractory MCL, guiding their integration into practice after targeted therapy failure.

This case report and literature review details the diagnosis and management of central nervous system involvement in MCL, a rare and aggressive manifestation with a poor prognosis.

This case report of non-nodal CNS MCL mimicking autoimmune or paraneoplastic encephalitis highlights the need to consider lymphoma in the differential diagnosis of complex neurological syndromes.

This review details Bortezomib's multiple anti-cancer mechanisms and significant toxicities, highlighting the need for next-generation proteasome inhibitors with better therapeutic windows for treating mantle cell lymphoma.

This review synthesizes the evolution of BTK-targeted therapies, from covalent inhibitors to non-covalent agents and degraders, outlining current treatment paradigms and future combination strategies for frontline and relapsed MCL.

Reviewing AIM and SYMPATICO trials, the ibrutinib-venetoclax combination shows high efficacy in relapsed/refractory MCL, supporting a potential fixed-duration, MRD-guided treatment strategy.

This review summarizes the clinical development and efficacy of BTK inhibitors in MCL, detailing common resistance mutations and outlining future directions for this crucial targeted therapy class.

This preclinical, biophysical study characterizes bortezomib's binding to serum albumin, providing fundamental pharmacokinetic data with no direct clinical implications for treating MCL patients.

The first approval of odronextamab, a CD20xCD3 bispecific antibody, in other lymphomas introduces a promising off-the-shelf, T-cell engaging immunotherapy for potential use in relapsed/refractory MCL.

This review confirms MRD's strong prognostic value in MCL but cautions that technical limitations and the uncertain clinical significance of low-level disease currently prevent its routine use for treatment decisions.

This review summarizes the established efficacy and toxicities of CD19 CAR-T therapy in B-cell lymphomas, including MCL, while highlighting future research directions like novel targets and sequencing with bispecifics.

This case report demonstrates that MCL can cause severe renal failure via both direct infiltration and paraneoplastic glomerulonephritis, underscoring the need for kidney biopsy in unexplained nephropathy.

A rare case of composite MCL and lymphoplasmacytic lymphoma in bone marrow highlights the necessity of advanced diagnostics like NGS and FISH to differentiate from MCL with plasmacytic differentiation.

This retrospective case series strengthens the link between ibrutinib and delayed-onset uveitis, a potentially vision-threatening toxicity that resolves upon drug cessation, highlighting a key clinical management consideration.

Analysis of European MCL Network trial data shows specific gene mutations predict patient outcomes, providing a genetic basis for risk stratification to guide therapy selection beyond clinical scores.

This phase 1 trial establishes the safety and preliminary efficacy of combining the HDAC inhibitor abexinostat with ibrutinib in relapsed/refractory MCL, suggesting a potential new BTKi-based combination strategy.

The polatuzumab-based regimen, Pola-R-mini-CHP, demonstrated efficacy in elderly relapsed/refractory MCL, offering a potential new ADC-chemoimmunotherapy option for this difficult-to-treat population.

Quantitative measurement of Cyclin D1 protein reveals that higher levels are paradoxically associated with better overall survival, establishing a novel, independent prognostic biomarker for MCL risk stratification.